Zepbound 15 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FAKNQ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,525
Award facts
- Contract value 100% obligated
- $11,524.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $11,524.75 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 15 mg/0.5 mL pen injections on January 21, 2026, with an ultimate completion date of January 22, 2026. This is a firm fixed-price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's parent organization, Cencora, Inc. (doing business as AmerisourceBergen), which holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 31, 2031, serving as the comprehensive vehicle for pharmaceutical and medical supply deliveries to support military healthcare programs globally.
AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's extensive contract portfolio with the DLA demonstrates its capability to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies. This particular delivery order for Zepbound, an FDA-approved glucagon-like peptide-1 receptor agonist used for weight management, reflects the Defense Health Agency's ongoing need for pharmaceutical support across its healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FAKNQ?
SPE2DR26FAKNQ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FAKNQ worth?
The government has obligated $11,525 on SPE2DR26FAKNQ.
Is contract SPE2DR26FAKNQ an order under another contract?
Yes. SPE2DR26FAKNQ is a delivery order under SPE2DR25D1201, an indefinite delivery contract.
Was contract SPE2DR26FAKNQ competed?
The extent of competition for SPE2DR26FAKNQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award